Results 41 to 50 of about 80,161 (286)
British Journal of Clinical Pharmacology, 2023 Recent case reports have suggested that sodium‐glucose co‐transporter 2 (SGLT2) inhibitors may interact with statins to increase their risk of myotoxicity.
Christopher A Gravel +4 more
semanticscholar +1 more source
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]
Diabetes Therapy, 2019 Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou +2 more
openaire +2 more sources
The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure [PDF]
Cureus, 2021 Sodium-glucose co-transporter-2 (SGLT2) inhibitors have evolved over the years, based on data from several randomized, double-blinded, placebo-controlled clinical trials. Formerly used primarily for blood sugar control in patients with diabetes, they are now used to decrease the risk of hospitalization for heart failure (HF), or of death from ...
Fadiran, Olusayo, Nwabuo, Chike
openaire +2 more sources
International Journal of Molecular Sciences, 2022 Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transporter 2.
S. Feijóo-Bandín +10 more
semanticscholar +1 more source
Cardiology Journal, 2023 Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica +24 more
doaj +1 more source
Critical Care, 2023 Sodium glucose co-transporter-2 (SGLT2) inhibitors improve long-term cardiovascular and renal outcomes in individuals with type 2 diabetes. However, the safety of SGLT2 inhibitors in ICU patients with type 2 diabetes is uncertain.
J. Mårtensson +8 more
semanticscholar +1 more source
Effects of sodium glucose co-transporter 2 inhibitors on the kidney [PDF]
Diabetes and Vascular Disease Research, 2018 Sodium–glucose cotransporter 2 inhibitors are antihyperglycaemic medications with an emerging evidence base for cardiovascular and kidney disease risk reduction. Sodium–glucose cotransporter 2 inhibitors medications lower plasma glucose by inhibiting glucose reabsorption in the proximal tubule of the kidney independent of insulin.
Natalia, de Albuquerque Rocha +4 more
openaire +2 more sources
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study
JRSM Open, 2016 Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
Amira Obeid +3 more
doaj +1 more source
Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
Journal of Education, Health and Sport, 2022 Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski +3 more
doaj +1 more source
European Journal of Heart Failure, 2021 Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and ...
D. Tomasoni +14 more
semanticscholar +1 more source